95 related articles for article (PubMed ID: 23167872)
1. Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history.
Ghiorzo P; Pastorino L; Queirolo P; Bruno W; Tibiletti MG; Nasti S; Andreotti V; ; Paillerets BB; Bianchi Scarrà G
Pigment Cell Melanoma Res; 2013 Mar; 26(2):259-62. PubMed ID: 23167872
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Molecular Characterization of Microphthalmia-associated Transcription Factor (MITF)-related Renal Cell Carcinoma.
Lang M; Vocke CD; Ricketts CJ; Metwalli AR; Ball MW; Schmidt LS; Linehan WM
Urology; 2021 Mar; 149():89-97. PubMed ID: 33242557
[TBL] [Abstract][Full Text] [Related]
3. MITF E318K: A rare homozygous case with multiple primary melanoma.
Wallingford CK; Maas EJ; Howard A; DeBortoli E; Bhanja D; Lee K; Mothershaw A; Jagirdar K; Willett R; Betz-Stablein B; Sturm RA; Soyer HP; McInerney-Leo AM
Pigment Cell Melanoma Res; 2024 Jan; 37(1):68-73. PubMed ID: 37635363
[TBL] [Abstract][Full Text] [Related]
4. DNA damage remodels the MITF interactome to increase melanoma genomic instability.
Binet R; Lambert JP; Tomkova M; Tischfield S; Baggiolini A; Picaud S; Sarkar S; Louphrasitthiphol P; Dias D; Carreira S; Humphrey TC; Fillipakopoulos P; White R; Goding CR
Genes Dev; 2024 Feb; 38(1-2):70-94. PubMed ID: 38316520
[TBL] [Abstract][Full Text] [Related]
5. The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma.
Hubert JN; Suybeng V; Vallée M; Delhomme TM; Maubec E; Boland A; Bacq D; Deleuze JF; Jouenne F; Brennan P; McKay JD; Avril MF; Bressac-de Paillerets B; Chanudet E
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34067022
[No Abstract] [Full Text] [Related]
6. Aggregation of melanoma tumour site within Western Australian families.
Ward SV; Drill EN; Begg CB
Cancer Epidemiol; 2024 Jun; 90():102580. PubMed ID: 38701695
[TBL] [Abstract][Full Text] [Related]
7. Epidemiological and genetic factors underlying melanoma development in Italy.
Palmieri G; Colombino M; Casula M; Budroni M; Manca A; Sini MC; Lissia A; Stanganelli I; Ascierto PA; Cossu A
Melanoma Manag; 2015 May; 2(2):149-163. PubMed ID: 30190844
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations.
Potrony M; Puig-Butille JA; Aguilera P; Badenas C; Tell-Marti G; Carrera C; Javier Del Pozo L; Conejo-Mir J; Malvehy J; Puig S
JAMA Dermatol; 2016 Apr; 152(4):405-12. PubMed ID: 26650189
[TBL] [Abstract][Full Text] [Related]
9. A germline oncogenic MITF mutation and tumor susceptibility.
Paillerets BB; Lesueur F; Bertolotto C
Eur J Cell Biol; 2014; 93(1-2):71-5. PubMed ID: 24290354
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of the E318K and V320I MITF germline mutations in Polish cancer patients and multiorgan cancer risk-a population-based study.
Gromowski T; Masojć B; Scott RJ; Cybulski C; Górski B; Kluźniak W; Paszkowska-Szczur K; Rozmiarek A; Dębniak B; Maleszka R; Kładny J; Lubiński J; Dębniak T
Cancer Genet; 2014 Apr; 207(4):128-32. PubMed ID: 24767713
[TBL] [Abstract][Full Text] [Related]
11. MITF E318K's effect on melanoma risk independent of, but modified by, other risk factors.
Berwick M; MacArthur J; Orlow I; Kanetsky P; Begg CB; Luo L; Reiner A; Sharma A; Armstrong BK; Kricker A; Cust AE; Marrett LD; Gruber SB; Anton-Culver H; Zanetti R; Rosso S; Gallagher RP; Dwyer T; Venn A; Busam K; From L; White K; Thomas NE;
Pigment Cell Melanoma Res; 2014 May; 27(3):485-8. PubMed ID: 24406078
[TBL] [Abstract][Full Text] [Related]
12. MITF mutations associated with pigment deficiency syndromes and melanoma have different effects on protein function.
Grill C; Bergsteinsdóttir K; Ogmundsdóttir MH; Pogenberg V; Schepsky A; Wilmanns M; Pingault V; Steingrímsson E
Hum Mol Genet; 2013 Nov; 22(21):4357-67. PubMed ID: 23787126
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic characterization of nevus and tumor patterns in MITF E318K mutation carrier melanoma patients.
Sturm RA; Fox C; McClenahan P; Jagirdar K; Ibarrola-Villava M; Banan P; Abbott NC; Ribas G; Gabrielli B; Duffy DL; Peter Soyer H
J Invest Dermatol; 2014 Jan; 134(1):141-149. PubMed ID: 23774529
[TBL] [Abstract][Full Text] [Related]
14. Exploring the hereditary background of renal cancer in Denmark.
Christensen MB; Wadt K; Jensen UB; Lautrup CK; Bojesen A; Krogh LN; Overeem Hansen TV; Gerdes AM
PLoS One; 2019; 14(4):e0215725. PubMed ID: 31034483
[TBL] [Abstract][Full Text] [Related]
15. Cancer risks associated with the germline MITF(E318K) variant.
Guhan SM; Artomov M; McCormick S; Njauw C-; Stratigos AJ; Shannon K; Ellisen LW; Tsao H
Sci Rep; 2020 Oct; 10(1):17051. PubMed ID: 33051548
[TBL] [Abstract][Full Text] [Related]
16. Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF.
Mangas C; Potrony M; Mainetti C; Bianchi E; Carrozza Merlani P; Mancarella Eberhardt A; Maspoli-Postizzi E; Marazza G; Marcollo-Pini A; Pelloni F; Sessa C; Simona B; Puig-Butillé JA; Badenas C; Puig S
Br J Dermatol; 2016 Nov; 175(5):1030-1037. PubMed ID: 27473757
[TBL] [Abstract][Full Text] [Related]
17. Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients.
Ciccarese G; Dalmasso B; Bruno W; Queirolo P; Pastorino L; Andreotti V; Spagnolo F; Tanda E; Ponti G; Massone C; Drago F; Parodi A; Ghigliotti G; Pizzichetta MA; Ghiorzo P;
J Transl Med; 2020 Feb; 18(1):78. PubMed ID: 32054529
[TBL] [Abstract][Full Text] [Related]
18. Melanoma genetics.
Read J; Wadt KA; Hayward NK
J Med Genet; 2016 Jan; 53(1):1-14. PubMed ID: 26337759
[TBL] [Abstract][Full Text] [Related]
19. The MITF, p.E318K Variant, as a Risk Factor for Pheochromocytoma and Paraganglioma.
Castro-Vega LJ; Kiando SR; Burnichon N; Buffet A; Amar L; Simian C; Berdelou A; Galan P; Schlumberger M; Bouatia-Naji N; Favier J; Bressac-de Paillerets B; Gimenez-Roqueplo AP
J Clin Endocrinol Metab; 2016 Dec; 101(12):4764-4768. PubMed ID: 27680874
[TBL] [Abstract][Full Text] [Related]
20. Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families.
Potjer TP; Bollen S; Grimbergen AJEM; van Doorn R; Gruis NA; van Asperen CJ; Hes FJ; van der Stoep N;
Int J Cancer; 2019 May; 144(10):2453-2464. PubMed ID: 30414346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
